Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2005-07-05
2005-07-05
Mosher, Mary E. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C424S232100, C424S208100, C424S281100, C435S235100, C435S236000, C435S320100
Reexamination Certificate
active
06913752
ABSTRACT:
The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen.
REFERENCES:
patent: 5155020 (1992-10-01), Paoletti
patent: 5185146 (1993-02-01), Altenburger
patent: 5494807 (1996-02-01), Paoletti et al.
patent: 5789245 (1998-08-01), Chang et al.
patent: WO9702355 (1997-02-01), None
patent: WO 98/56919 (1998-12-01), None
patent: WO 00 28016 (2000-05-01), None
patent: WO 01 68820 (2001-09-01), None
patent: WO 02/24224 (2002-03-01), None
Eo et al, The Journal of Immunology 166:5473-5479, May 2001.
Holzer et al (Journal of Virology 73:4536-4542, 1999).
Antoine et al (Virology 244:365-96, 1998).
Gilbert et al (Biol. Chem. 380:299-303, 1999).
Moss et al. “Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates.” Advances in Experimentaly Medicine and Biology 397:7-13, 1996.
Wyatt et al (PNAS 101:4590-4595, 2004).
Earl et al (Nature 428:182-185, 2004).
Stittelaar et al. Vaccine 19:3700-3709, 2001.
Behera AK. Kumar M, Lockey RF and Mohapatra SS (2002) Hum. Gene Ther. Sep. 20; 13(14):1697-709.
Belyakov IM, Earl P, Dzutsev A, Kuznetsov VA, Lemon M, Wyatt LS, Snyder JT, Ahlers JD, Franchini G, Moss B and Berzofsky JA. (2003) Proc. Natl. Acad. Sci. 100:9458-9463.
Hanke T, Samuel RV, Blanchard TJ, Neumann VC, Allen TM, Boyson JE, Sharpe SA, Cook N, Smith GL, Watkins DI, Cranage MP and McMichael AJ (1999) Journal of Virology 73:7524-7532.
Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, Hannan CM, Becker M, Sinden R, Smith GL and Hill AVS. (1998) Nature Medicine 4:397-402.
Mayr, A., Zbl Vet B 23, 417-430 (1976).
Blanchard, J.T., et al., Journal of General Virology, 79, 1159-1167 (1998).
Caroll, W.M. and Moss, B., Virology 238, 198-211 (1997).
Meyer, H., et al., Journal of general virology, 72, 1031-1038 (1991).
Bender, et al., Journal of Virology, vol. 70, No. 9, pp. 6418-6424 (Sep. 1, 1996).
Schneider, et al. (1998), Nature Medicine 4, 397-402.
Sutter, et al. (1994), Vaccine 12, 1032-1040.
Stittelaar, et al. Vaccine 19:3700-3709, 2001.
Sutter and Moss Proc. Natl. Acad. Sci. USA 89:10847-51, 1992.
Schieflinger, et al, Proc. Natl. Acad. Sci. USA 89:9977-81, 1992.
Merchlinsky, et al. Virology 190:522-6, 1992.
Chaplin Paul
Howley Paul
Meisinger Christine
Bavarian Nordic A/S
Mosher Mary E.
The Firm of Hueschen and Sage
LandOfFree
Modified Vaccinia Ankara virus variant does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified Vaccinia Ankara virus variant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified Vaccinia Ankara virus variant will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3378525